Meet the Founders, Investors, and Operators Joining the Cure Community

Cure's member community continues to grow, not just in size, but in the range of experience and points of view. Recent members include founders developing new therapeutics and platforms, investors backing early innovation, operators scaling complex businesses, and communications leaders shaping how science shows up in the world.

What connects them is not a single role, but participation in our ecosystem designed for progress. Members engage directly with one another to advance their businesses and initiatives, and can connect collectively through focused discussions around shared topics of interest, both professional and personal.

This is the practical power of an ecosystem approach to advancing cures: progress doesn’t happen in isolation, but through interaction across disciplines, incentives, and stages of development. Cure’s membership is built to support that reality.

Below is a snapshot of who’s recently joined Cure and what they’re building, backing, and exploring.

Perpetual is a digital design and development agency working with healthcare organizations to build clear, usable technology. The team helps translate complex data, workflows, and ideas into practical digital experiences for patients, clinicians, and internal teams. Perpetual has partnered with organizations including The American Medical Association, HIMSS, Black Women’s Health Imperative, The NYC Department of Mental Health, and multiple healthcare startups.

Angel Hive is an angel syndicate that invests in women-led startups improving the lives of women and girls.

Applied PharmacoDynamics is developing first-in-class antibody therapies for substance use disorders, beginning with cocaine use disorder. Its lead asset is in the late preclinical stage and represents a novel, non-addictive, biologically grounded therapeutic approach aimed at reducing relapse and improving long-term outcomes, addressing a major unmet medical and societal need.

Synthis Therapeutics is a preclinical biotech developing a novel antibody drug conjugate to treat fibrotic and inflammatory diseases, including IPF and myelofibrosis. Its lead program selectively blocks TGF-beta signaling at the cellular level to improve efficacy while reducing toxicity. The company holds nine issued patents and is currently raising a $25M Series A for first-in-human clinical trials in MF patients.

At Roseman University’s College of Dental Medicine, Dr. Patil focuses on competency-based education, translational research, and digital health innovation, with the goal of improving oral health outcomes through clinical excellence and applied research.

Tinker Therapeutics is advancing multi-targeting RNA medicines to address delivery and durability limitations in current monotherapies. Its FORGE platform enables single-molecule oligonucleotides capable of silencing multiple targets simultaneously. The company is pre-seed and focused on CNS and retinal diseases with seven current preclinical pipeline programs and a recent first licensing agreement. Its founders won first place at the 2024 Eli Lilly and Company Genetic Medicine Grand Challenge.

New Dawn Communications is a public relations and marketing consultancy serving healthcare companies across biotech, pharma, medtech, provider systems, and nonprofits. The firm specializes in integrated corporate and product communications, supporting clients at every stage of growth and helping bring their stories to the right audiences at the right time.

Rhizome AI provides regulatory intelligence for life sciences teams. Its platform uses AI to answer regulatory, clinical, and quality questions with fully cited insights drawn from thousands of indexed sources, serving customers from early startups to global pharmaceutical companies.

DeepEcho is a medical AI company focused on making prenatal ultrasound accurate, affordable, and accessible worldwide. Its FDA-cleared ultrasound software automates fetal imaging, quality assessment, and measurements, reducing operator dependency and improving reliability across care settings. By combining regulatory-grade AI with large-scale longitudinal imaging, DeepEcho enables both high-quality routine scans and the discovery of new biomarkers for serious maternal and fetal conditions.

Wendy Diller is a journalist and communications consultant who specializes in the life sciences industry, across the medical devices, diagnostics and precision medicine, and biotechnology sub-sectors. She writes for The MedTech Strategist and its sister publication, Market Pathways. Through her company LifeScInnovation, she advises life sciences companies on communicating complex science and strategy to diverse stakeholders.

CobiCure, a non-profit company of Advancium Health Network, is a mission-driven innovation accelerator dedicated to transforming pediatric healthcare and rare disease treatment. The company prioritizes children’s well-being over financial returns by in-licensing, acquiring, or co-developing medical devices and therapeutics that reduce morbidity and mortality. Through philanthropic funding and strategic partnerships, CobiCure provides the infrastructure, expertise, and regulatory support needed to advance overlooked solutions from R&D through approval. The company is seeking partners to join their mission of ensuring every child has access to life-changing treatments.

333VC is a venture investment syndicate focused on disruptive healthcare platform innovations, investing from pre-seed through Series A. The firm gives accredited investors the ability to choose which deals to participate in through SPVs, with a $5,000 minimum. 333VC’s core objective is to provide strategic capital that helps move the U.S. healthcare system toward better outcomes, greater efficiency, and lower cost.

Hunter is a fractional CFO who works with early-stage startups on fundraising, financial planning, and go-to-market strategy through his firm, Mountain Cutter. Over the course of his career, he has supported dozens of companies and helped raise more than $500 million. He also serves as CFO of the Global Ultrasound Institute, a point-of-care ultrasound education and training SaaS platform with AI-enabled automation for ultrasound workflows, which is currently raising a $1.5 million SAFE ahead of a $3–5 million seed round.

Seek Labs is a TechBio company approaching disease as a dynamic problem that requires rapidly adaptable systems, not static solutions. Our integrated disease response platform combines BioSeeker, an Al-powered discovery engine that maps and tracks pathogen evolution and vulnerabilities; PTAP, programmable, CRISPR-based therapeutics that neutralize pathogens; and Seeklt, point-of care-molecular diagnostics that are deployable anywhere. By converting biological information into actionable data, Seek Labs’ platforms detect, protect, and counter disease faster than it can spread.

Veritas Quest works with health tech founders and leadership teams navigating rapid growth, complexity, and constant uncertainty. Drawing on Harvard’s Adaptive Leadership framework, the firm helps teams strengthen decision-making under pressure, align quickly around tough priorities, and build high performance without burnout. The work supports founders as they scale, turning challenges such as team tension, unclear authority, or shifting policies into opportunities for innovation, resilience, and sustainable growth. The goal is not just to grow fast, but to grow well, with leadership capacity that adapts, engaged teams, and organizations that can thrive in complexity.

32 Biosciences is a gastrointestinal biotech focused on diseases of the colon, where prevention and treatment options remain limited. Built on decades of peer-reviewed research, the company is developing CS-0003, a first-in-class mucosal immune modulator designed to restore and protect the gut’s immune barrier without disrupting the healthy microbiome. The program is moving toward the clinic with initial targets including GI surgical site infections, inflammatory bowel disease, and colon cancer recurrence, supported by a proprietary GI discovery engine.

Orangefiery helps leaders of growing companies articulate their stories through brand strategy, corporate narratives, presentations, websites, and thought leadership programs.

PolyCypher Health's mission is to predict, prevent, and cure chronic diseases based on the unique makeup of each individual. Chronic diseases account for the majority of deaths and healthcare costs, yet many are preventable. To address this, the company has developed a predictive AI platform based on genomics and health data, along with HealthyMe.ai, a genetic risk-prediction test. PolyCypher provides personalized insights to support longer healthspan and lifespan, including individualized risk profiles for chronic diseases and cancers, tailored preventive guidance, and ongoing health tracking. The company works with healthcare enterprises, including concierge and longevity clinics, digital health companies, health systems, and insurers, as well as biopharma firms.

XiaoBio is an early-stage company developing novel oral therapeutics for malaria, leveraging advances in protein design and bioavailability to address resistance and expand treatment options. The field has seen encouraging progress, including positive Phase 3 results from Novartis. Even so, the team believes more oral treatment options are critical, especially as resistance to existing therapies grows. XiaoBio is currently testing in vitro biology for its first non-optimized candidates.

VentureWell supports the cultivation of science and technology inventors and the innovation and entrepreneurship ecosystems critical to their success. Since its founding in 1995, VentureWell has funded or trained over 19,000 early-stage science and technology inventors and innovators, resulting in the emergence of more than 6,100 ventures with groundbreaking technological advancements in fields like biomedicine and healthcare, sustainable energy and materials, and solutions for low-resource settings. The ventures it has supported have raised subsequent funds totaling more than $7.8 billion and are reaching millions of people globally.

Rarecells develops liquid biopsy technologies to improve early cancer detection, where many existing tests miss early-stage disease due to limited signal. Its proprietary ISET platform captures circulating tumor cells often discarded in standard plasma-based testing, recovering tumor DNA that would otherwise be lost. By combining DNA from intact circulating tumor cells with circulating tumor DNA within existing workflows, Rarecells aims to provide a more complete and earlier view of cancer biology from a single blood draw.

By Mnemosyne is an interdisciplinary innovation consultancy supporting founders, organizations, and municipalities at the intersection of business, design, storytelling, and societal health. Rooted in both the arts and sciences, through imagination, remembrance, and foresight, it distills complexity, beautifies, engages, and fosters dynamic futures. Its human-centered methodology and experiential series—Silo Solving—bridges gaps and facilitates cross-disciplinary, cross-functional, and cross-sector experiences. Additional offering areas include: Brand and Innovation Architecture (e.g., 360° Design, Strategic Planning), Sustainability Advisory (e.g., LEED, TRUE, SEA frameworks), and Paradigm Design, for what is a paradigm shift with no other system in place.

Dr. Victoria Zyulina is an immunology-focused physician-scientist with more than a decade of experience bridging discovery research and translational development in human immunology. As a faculty member in the Department of Microbiology at Icahn School of Medicine at Mount Sinai, she develops scalable, physiologically relevant human primary cell platforms, particularly ex vivo dendritic cell systems derived from hematopoietic stem cells, to address the predictivity gap of animal models and conventional in vitro assays. Her work supports target validation, mechanism-of-action studies, and translational decision-making across the early stages of the drug and vaccine development pipeline.

NightingaleMD is an AI care management platform that extends care beyond the clinical visit on behalf of healthcare providers. Fully integrated into provider workflows and the patient’s medical record, its voice-based system acts as a provider-directed, always-on care manager, guiding patients through care plans and supporting follow-through on medications, appointments, and transitions of care. Each interaction is clinically informed and personalized through access to the patient’s full record. With clinical oversight and provider-defined protocols, NightingaleMD helps address care manager shortages by extending provider reach at scale. The company is a CMS Voice AI Pledge participant.